Why Diabetic Foot Wounds Stop Healing: Insights from Surgeon Yaroslav Popovych’s Systemic Approach

Key Takeaways

Approximately 1.6 million Americans develop a diabetic foot ulcer (DFU) each year, making diabetic foot disease one of the most serious complications of diabetes.
Standard treatment focuses primarily on local wound management but may not fully address underlying metabolic and inflammatory dysfunction.
Research by surgeon Yaroslav Popovych suggests that adding cryopreserved cord blood preparations to standard surgical treatment may improve outcomes in selected patients with diabetic foot syndrome (Popovych, 2014).
Emerging evidence from regenerative medicine supports continued investigation of biologic therapies for difficult-to-heal diabetic foot ulcers (Caporusso et al., 2025; Tong et al., 2025).
Early recognition and correction of systemic factors such as inflammation, impaired circulation, and poor glycemic control may improve healing outcomes.
Current evidence remains promising but evolving, and additional large-scale studies are needed before these therapies can be considered standard care.

Introduction

Diabetic Foot

Diabetic foot ulcers (DFUs) remain among the most devastating complications of diabetes mellitus. These wounds are associated with infection, hospitalization, reduced quality of life, and increased risk of lower-extremity amputation. Despite advances in wound care, many ulcers fail to heal even when patients receive treatment consistent with current clinical guidelines (International Working Group on the Diabetic Foot [IWGDF], 2023; Lavery et al., 2024).

Conventional diabetic foot management focuses primarily on local interventions such as wound debridement, infection control, pressure offloading, vascular assessment, and advanced wound dressings. These interventions are essential and supported by evidence-based guidelines. However, clinicians frequently encounter patients whose wounds remain stalled despite appropriate care, suggesting that factors beyond the wound itself may influence healing (Lavery et al., 2024).

Doctor Yaroslav Popovych

Surgeon Yaroslav Popovych, Candidate of Medical Sciences and former practitioner at Ivano-Frankivsk City Clinical Hospital No. 1 in Ukraine, observed this challenge repeatedly during years of treating patients with advanced diabetic foot syndrome.

“You can see two patients with very similar wounds, but their recovery may progress very differently because healing depends on what is happening inside the body.”

According to Popovych:

“When metabolic issues are identified early, the tissue often responds much better to treatment.”

These observations became the foundation for his investigation into systemic approaches that complement traditional surgical management.

Why Many Diabetic Foot Wounds Fail to Heal

Diabetic foot ulcers develop through a combination of peripheral neuropathy, vascular disease, immune dysfunction, and repetitive tissue injury. Chronic hyperglycemia disrupts normal wound-healing pathways by impairing angiogenesis, increasing oxidative stress, reducing growth-factor activity, and prolonging inflammation (IWGDF, 2023).

As a result, some wounds become trapped in a chronic inflammatory state and fail to progress through the normal phases of healing. Even when clinicians successfully manage infection and local wound care, underlying metabolic abnormalities may continue to impair tissue repair.

This helps explain why two patients with similar-looking wounds can experience very different outcomes. Factors such as glycemic control, vascular status, systemic inflammation, nutritional health, and immune function often play a major role in determining whether healing progresses successfully (Lavery et al., 2024).

For patients, this means that what is happening inside the body may be just as important as what is visible on the wound surface.

Popovych’s Systemic Treatment Model

To address these challenges, Popovych explored whether correcting systemic biological abnormalities alongside conventional surgical treatment could improve outcomes in patients with diabetic foot syndrome.

His protocol combined standard surgical management with intramuscular administration of Cryocell-Cryocord, a cryopreserved cord blood-derived preparation containing biologically active growth factors and other cellular components (Popovych, 2014).

In a study involving 138 patients with type 2 diabetes and diabetic foot syndrome, patients receiving the cord blood preparation in addition to standard treatment experienced improved outcomes compared with patients receiving standard care alone (Popovych, 2014).

Reported findings included:

Approximately 16.5% fewer major lower-extremity amputations.
An average reduction of 10.5 treatment days.
A 25–30% reduction in insulin requirements.
Sustained benefits among a subset of patients during follow-up.

In the most severe cases, major amputation reportedly occurred less frequently among treated patients than among comparable controls (Popovych, 2014).

A subsequent analysis involving 158 patients reported reductions in inflammatory markers, improvements in red blood cell characteristics, enhanced protein-synthesis indicators, and earlier wound closure among patients with advanced diabetic foot syndrome (Popovych, 2014).

Although these findings are encouraging, they should be interpreted cautiously. The studies were conducted within specific healthcare settings, involved relatively modest patient populations, and require further independent validation before definitive conclusions can be drawn.

How Cord Blood-Derived Therapies May Support Healing

Researchers believe cord blood-derived therapies may influence several biological pathways involved in wound repair.

Potential mechanisms include:

Promotion of angiogenesis and new blood vessel formation.
Regulation of excessive inflammatory responses.
Enhancement of tissue regeneration.
Improvement of microcirculation.
Reduction of oxidative stress.

These mechanisms are biologically plausible and supported by laboratory and translational research. However, the precise pathways responsible for clinical improvements in diabetic foot ulcers remain under investigation, and more research is needed to determine which patients may benefit most from these therapies (Tong et al., 2025).

Importantly, biologic therapies are not intended to replace established treatments such as debridement, infection management, vascular care, and pressure offloading. Rather, they are being investigated as adjunctive therapies that may help improve the body’s healing environment.

Emerging Evidence from Regenerative Medicine

Popovych’s findings align with growing scientific interest in regenerative medicine approaches for chronic wound management.

A 2025 multicenter randomized controlled trial published in Wound Repair and Regeneration evaluated cryopreserved ultra-thick human amniotic membrane in patients with complex diabetic foot ulcers. Investigators reported improved healing outcomes compared with standard treatment, suggesting that biologically active tissue products may offer therapeutic benefits in selected patients (Caporusso et al., 2025).

Although the product studied differed from Cryocell-Cryocord, both therapies are designed to improve the biological environment necessary for wound repair. The findings support continued investigation into regenerative approaches rather than serving as direct validation of any single therapy.

Similarly, a systematic review and meta-analysis examining stem cell therapies for diabetic foot ulcers concluded that regenerative medicine approaches show promise for improving healing outcomes, while emphasizing the need for larger, high-quality clinical trials before widespread adoption (Tong et al., 2025).

Additional research involving cryopreserved umbilical cord products has reported encouraging healing rates and low amputation rates among patients with severe diabetic foot ulcers complicated by osteomyelitis, although investigators also noted the need for further confirmatory studies (Marston et al., 2020).

Taken together, these studies suggest that regenerative therapies may eventually become valuable additions to multidisciplinary diabetic foot care. However, the evidence remains insufficient to support routine use across all patient populations.

What Are the Limitations of the Existing Research?

Although the reported outcomes are promising, several limitations should be considered.

Most studies evaluating regenerative therapies for diabetic foot ulcers involve relatively small patient populations. Differences in study design, patient selection criteria, treatment protocols, and outcome measures make direct comparisons challenging.

Furthermore, many studies have been conducted at a limited number of centers, and some findings have not yet been replicated in large multicenter trials. Questions also remain regarding long-term effectiveness, cost-effectiveness, optimal patient selection, and regulatory considerations.

For these reasons, regenerative therapies should currently be viewed as emerging adjunctive treatments rather than replacements for established standards of care.

How This Fits with Current Guidelines

Current diabetic foot guidelines emphasize comprehensive multidisciplinary care, including blood glucose management, infection control, vascular assessment, pressure offloading, patient education, and timely surgical intervention when necessary (IWGDF, 2023; Lavery et al., 2024).

The International Working Group on the Diabetic Foot and the Wound Healing Society continue to identify these measures as the foundation of evidence-based diabetic foot management (IWGDF, 2023; Lavery et al., 2024).

Popovych’s work complements this broader philosophy by emphasizing that successful healing may depend not only on local wound treatment but also on correcting systemic abnormalities that interfere with tissue repair.

Rather than challenging existing guidelines, this approach expands on the concept of treating the whole patient rather than focusing exclusively on the wound itself.

Clinical Implications

One of the most important lessons from Popovych’s research is that healing should not be viewed as a purely local process.

For clinicians, this means evaluating:

Glycemic control.
Vascular health.
Nutritional status.
Inflammatory burden.
Immune function.
Overall metabolic stability.

For patients, it reinforces the importance of early intervention, adherence to diabetes management plans, regular foot examinations, and prompt treatment when wounds develop.

While regenerative biologic therapies remain an evolving area of medicine, evidence increasingly suggests that addressing systemic factors may improve the body’s ability to heal chronic wounds.

Diabetic Foot Wounds and Systemic Treatment Approaches (FAQs)

Understanding Diabetic Foot Ulcers

What is a diabetic foot ulcer?

A diabetic foot ulcer is an open sore or wound that develops on the foot of a person with diabetes. These ulcers commonly occur because diabetes can damage nerves (neuropathy), reduce blood flow, and impair the body’s ability to heal.

How common are diabetic foot ulcers?

Diabetic foot ulcers are among the most common complications of diabetes. Approximately 1.6 million Americans develop a diabetic foot ulcer each year, and many require specialized wound care to prevent serious complications.

Why do diabetic foot ulcers develop?

Most diabetic foot ulcers result from a combination of nerve damage, poor circulation, repetitive pressure, foot deformities, and impaired immune function. Because patients may not feel pain normally, minor injuries can go unnoticed and progress into chronic wounds.

Why do some diabetic foot wounds stop healing?

Healing can stall when underlying problems such as chronic inflammation, poor blood sugar control, reduced blood flow, infection, or metabolic dysfunction interfere with the body’s natural repair processes.

Can a wound look small but still be serious?

Yes. The visible wound may not reflect the full extent of tissue damage underneath. Even small ulcers can become infected or lead to significant complications if not treated promptly.

Standard Treatment and Its Limitations

What is the standard treatment for diabetic foot ulcers?

Standard treatment typically includes:

Debridement (removal of dead tissue)
Infection control
Pressure offloading
Blood sugar management
Vascular assessment
Advanced wound dressings when appropriate

Why doesn’t standard treatment always work?

Although standard care is highly effective for many patients, some wounds remain stalled because systemic issues such as inflammation, poor circulation, or metabolic abnormalities continue to impair healing.

What does “treating the whole patient” mean?

It means addressing factors beyond the wound itself, including blood glucose levels, vascular health, inflammation, nutrition, immune function, and other medical conditions that may affect healing.

Can poor blood sugar control slow healing?

Yes. Elevated blood glucose levels can impair immune function, damage blood vessels, increase inflammation, and slow tissue repair.

How important is circulation?

Good circulation is essential because oxygen and nutrients must reach injured tissues for healing to occur. Poor blood flow is one of the strongest predictors of delayed wound healing.

Yaroslav Popovych’s Research

Who is Yaroslav Popovych?

Yaroslav Popovych is a surgeon and Candidate of Medical Sciences who conducted research investigating systemic biological approaches to diabetic foot treatment in addition to conventional surgical care.

What observation led to his research?

Popovych noticed that patients with similar-looking wounds often experienced very different healing outcomes, suggesting that internal metabolic and inflammatory factors play an important role in recovery.

What was unique about his approach?

His work focused on combining standard surgical treatment with systemic biological support rather than concentrating exclusively on local wound management.

What is Cryocell-Cryocord?

Cryocell-Cryocord is a cryopreserved cord blood-derived biologic preparation containing growth factors and other biologically active components that were investigated as an adjunctive therapy.

What outcomes were reported in Popovych’s studies?

His research reported reductions in major amputations, shorter treatment duration, reduced insulin requirements, and earlier wound closure compared with standard treatment alone.

Regenerative Medicine and Healing

How might cord blood-derived therapies support healing?

Researchers believe these therapies may help promote angiogenesis, regulate inflammation, improve microcirculation, reduce oxidative stress, and support tissue regeneration.

Are these mechanisms proven?

Not entirely. While the biological rationale is strong, researchers continue studying the exact mechanisms responsible for clinical improvements.

Are other regenerative therapies being studied?

Yes. Researchers are evaluating:

Amniotic membrane products
Placental tissue therapies
Stem-cell-based treatments
Umbilical cord-derived biologics
Growth factor therapies

Does recent research support regenerative medicine for diabetic foot ulcers?

Several recent studies have reported encouraging results, including improved healing rates in difficult-to-treat ulcers. However, experts generally agree that larger studies are still needed.

Does regenerative medicine replace conventional wound care?

No. Current evidence suggests these therapies may serve as adjuncts to standard care rather than replacements for proven treatments such as debridement, infection control, vascular management, and offloading.

Safety, Availability, and Clinical Practice

Are cord blood-derived therapies approved everywhere?

No. Availability, regulatory approval, and clinical use vary significantly by country and healthcare system.

Are these treatments considered standard of care?

Not currently. Most regenerative therapies remain emerging treatment options and are still being evaluated through ongoing clinical research.

Should patients ask their doctor about biologic therapies?

Patients may wish to discuss all available treatment options with their healthcare team, including whether advanced wound-healing therapies may be appropriate for their specific situation.

What specialists are involved in diabetic foot care?

A multidisciplinary diabetic foot team may include:

Podiatrists
Endocrinologists
Vascular surgeons
Wound-care specialists
Infectious disease physicians
Diabetes educators
Orthopedic surgeons
Plastic surgeons

What is the most important takeaway from this research?

The key lesson is that successful healing often depends on more than wound care alone. Addressing systemic factors such as blood sugar control, inflammation, circulation, and overall metabolic health may improve outcomes and help preserve limbs in patients with diabetic foot disease.

Final Thoughts

Diabetic foot ulcers continue to represent a major healthcare challenge because treatment often focuses on the visible wound while underlying biological dysfunction persists.

Yaroslav Popovych’s research highlights the importance of addressing systemic metabolic and inflammatory factors alongside conventional surgical and wound-care interventions. His findings suggest that biologic therapies may help improve healing outcomes and reduce the risk of limb loss in selected patients, although further independent research is needed to confirm these benefits and define their role in modern diabetic foot management (Popovych, 2014).

At the same time, emerging studies involving amniotic membrane products, stem-cell therapies, and umbilical cord-derived biologics indicate growing interest in regenerative approaches that support the body’s natural healing processes (Caporusso et al., 2025; Marston et al., 2020; Tong et al., 2025).

As the science continues to evolve, one message remains clear: successful diabetic foot care requires treating the whole patient—not just the wound. Combining evidence-based local treatment with careful attention to systemic health may offer the best opportunity to improve healing, preserve limbs, and enhance quality of life for people living with diabetes.

References

Caporusso, J., Motley, T., Lantis, J. C., II, Heisler, S., Hicks, A., Wu, S. C., & Reyzelman, A. (2025). A multi-centre, randomised, controlled clinical trial assessing cryopreserved ultra-thick human amniotic membrane in the treatment of complex diabetic foot ulcers. Wound Repair and Regeneration, 33(6), e70110. https://doi.org/10.1111/wrr.70110

International Working Group on the Diabetic Foot. (2023). IWGDF guidelines on the prevention and management of diabetic foot disease. https://iwgdfguidelines.org/wp-content/uploads/2023/07/IWGDF-Guidelines-2023.pdf

Lavery, L. A., Suludere, M. A., Attinger, C. E., Malone, M., Kang, G. E., Crisologo, P. A., Peters, E. J. G., & Rogers, L. C. (2024). WHS guideline update: Diabetic foot ulcer treatment guidelines. Wound Repair and Regeneration, 32(1), 34–46. https://doi.org/10.1111/wrr.13133

Marston, W. A., Lantis, J. C., II, Wu, S. C., Nouvong, A., Clements, J. R., Lee, T. D., McCoy, N. D., Slade, H. B., & Tseng, S. C. G. (2020). One-year safety, healing and amputation rates of Wagner grade 3–4 diabetic foot ulcers treated with cryopreserved umbilical cord. Wound Repair and Regeneration, 28(4), 526–531. https://doi.org/10.1111/wrr.12809

Popovych, Y. O. (2014). Cryopreserved cord blood preparations in combined surgical treatment of purulent complications of type II diabetes mellitus. Problems of Cryobiology and Cryomedicine, 24(4), 332–340. https://doi.org/10.15407/cryo24.04.332

Tong, L., et al. (2025). Impacts of stem cells from different sources on wound healing in diabetic foot ulcers: A systematic review and meta-analysis. Frontiers in Genetics, 15, 1541992. https://doi.org/10.3389/fgene.2024.1541992